21 – 30 of 57
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
(
- Contribution to journal › Article
- 2021
-
Mark
Biomarker testing in MCI patients—deciding who to test
(
- Contribution to journal › Article
-
Mark
Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies
(
- Contribution to journal › Article
-
Mark
Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups
(
- Contribution to journal › Article
-
Mark
Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups
(
- Contribution to journal › Article
- 2020
-
Mark
Test–retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
(
- Contribution to journal › Article
-
Mark
Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
(
- Contribution to journal › Article
-
Mark
A clinical-radiological framework of the right temporal variant of frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
(
- Contribution to journal › Article